Science Explorer Back to mapMap
Discussion
Company · Huddinge · Sweden

Axcentua (Sweden)

axcentua.comROR OpenAlex
Research works
1
▼ 100% vs 2018-21
Citations
214
154.0 per fractional work
Top-10% rate
36.0%
all institutions 10.0%
Open access
46%
world 40%
International
46%
world 18%
Axcentua (Sweden)

Not ranked overall: Axcentua (Sweden) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does Axcentua (Sweden) work in?

In all years, 85% of research at Axcentua (Sweden) is in Health Sciences, 15% in Physical Sciences. Its largest fields are Medicine (77%), Engineering (15%), Nursing (8%).

Health Sciences: 1 fractional works · 84.6% of its workMedicine: 1 fractional works · 76.9% of its workNursing: 0 fractional works · 7.7% of its workPhysical Sciences: 0 fractional works · 15.4% of its workEngineering: 0 fractional works · 15.4% of its workALL ITS WORKAxcentua (Sweden)1fractional works, all years
Physical Sciences15%Health Sciences85%

Each ring splits the one inside it: the four domains of science, their fields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 2 domains and 3 fields, with their numbers
    1. Medicine176.9%
    2. Nursing07.7%
    1. Engineering015.4%
All of science, and how each field's share has moved since 1950: the Science domain explorer

What are the most cited papers from Axcentua (Sweden)?

The most cited paper from Axcentua (Sweden) is "3D pancreatic carcinoma spheroids induce a matrix-rich, chemoresistant phenotype offering a better model for drug testing" (Paola Longati, Xiaohui Jia, Johannes Eimer et al., 2013), with 396 citations. Next come "A phase I dose escalation trial of AXP107-11, a novel multi-component crystalline form of genistein, in combination with gemcitabine in chemotherapy-naive patients with unresectable pancreatic cancer" (51) and "Clinical candidate and genistein analogue AXP107‐11 has chemoenhancing functions in pancreatic adenocarcinoma through G protein‐coupled estrogen receptor signaling" (21).

Most cited papers
#PaperReleasedCitations
1 3D pancreatic carcinoma spheroids induce a matrix-rich, chemoresistant phenotype offering a better model for drug testing Paola Longati, Xiaohui Jia, Johannes Eimer et al. · BMC Cancer Open access 27 Feb 2013 396
2 A phase I dose escalation trial of AXP107-11, a novel multi-component crystalline form of genistein, in combination with gemcitabine in chemotherapy-naive patients with unresectable pancreatic cancer Matthias J. Löhr, Masoud Karimi, Brigitta Omazic et al. · Pancreatology 14 May 2016 51
3 Clinical candidate and genistein analogue AXP107‐11 has chemoenhancing functions in pancreatic adenocarcinoma through G protein‐coupled estrogen receptor signaling Fahmi Mesmar, Bingbing Dai, Ahmed Atef Ibrahim et al. · Cancer Medicine Open access 30 Sep 2019 21
4 The thyroid receptor β modulator GC-1 reduces atherosclerosis in ApoE deficient mice Kristina Kannisto, Stefan Rehnmark, Katharina Slätis et al. · Atherosclerosis 18 Oct 2014 19
All 4 most cited papers, with filters and sorting

Which research topics does Axcentua (Sweden) publish most on?

By volume: Pancreatic and Hepatic Oncology Research, Cancer Cells and Metastasis, 3D Printing in Biomedical Research and HER2/EGFR in Cancer Research.

Pancreatic and Hepatic O…0Pancreatic and Hepatic Oncology Research: 0 fractional worksCancer Cells and Metasta…0Cancer Cells and Metastasis: 0 fractional works3D Printing in Biomedical Research: 0 fractional worksHER2/EGFR in Cancer Research: 0 fractional worksFatty Acid Research and Health: 0 fractional worksCholesterol and Lipid Me…0Cholesterol and Lipid Metabolism: 0 fractional worksDrug Transport and Resistance Mechanisms: 0 fractional worksLung Cancer Treatments and Mutations: 0 fractional works
OncologyBiomedical EngineeringNutrition and DieteticsSurgery1 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Pancreatic and Hepatic Oncology Research Oncology 0 works
  2. 2 Cancer Cells and Metastasis Oncology 0 works
  3. 3 3D Printing in Biomedical Research Biomedical Engineering 0 works
  4. 4 HER2/EGFR in Cancer Research Oncology 0 works
  5. 5 Fatty Acid Research and Health Nutrition and Dietetics 0 works
  6. 6 Cholesterol and Lipid Metabolism Surgery 0 works
  7. 7 Drug Transport and Resistance Mechanisms Oncology 0 works
  8. 8 Lung Cancer Treatments and Mutations Pulmonary and Respiratory Medicine 0 works
  9. 9 Epigenetics and DNA Methylation Molecular Biology 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available46.2%not open53.8%

World: 40% of research is openly available.

with international co-authors46.2%domestic only53.8%

World: 18% is written across borders.

How has Axcentua (Sweden)'s research output changed?

Output in 2022-2025 was 100% lower than in 2018-2021.

2015

Other research institutions in Huddinge

All research institutions in Huddinge

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about Axcentua (Sweden). Posts are plain text and can be reported.